| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2024 | VRNO Verano Holdings Corp. | Miles Aaron Nathaniel | Chief Investment Officer | Sell | 6,842 | $1.38 | $9,428.28 | -2.0% | - | - | |
| Dec 3, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 21,495 | $36.68 | $788,436.60 | -52.6% | -14.3% | +20.9% | |
| Dec 3, 2024 | VRNO Verano Holdings Corp. | Archos George Peter | Chief Executive Officer | Sell | 8,751 | $1.38 | $12,095.63 | - | - | - | |
| Dec 3, 2024 | VRNO Verano Holdings Corp. | Kalesnik Laura Marie | See Remarks | Sell | 5,855 | $1.38 | $8,092.78 | -3.6% | - | - | |
| Dec 3, 2024 | VRNO Verano Holdings Corp. | Thompson Destiny Lynn | Chief People Officer | Sell | 2,822 | $1.38 | $3,900.57 | -2.8% | - | - | |
| Dec 2, 2024 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $370.51 | $3,705,074.31 | -35.6% | -16.2% | +28.1% | |
| Dec 2, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 2,054 | $33.56 | $68,932.24 | -1.1% | +31.9% | +17.7% | |
| Dec 2, 2024 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Sell | 155 | $0.77 | $118.89 | -0.4% | -28.0% | +68.0% | |
| Dec 2, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 33,513 | $33.38 | $1,118,653.89 | -50.0% | +31.9% | +17.7% | |
| Dec 2, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L64 | Chief Medical Officer | Sell | 5,421 | $5.54 | $30,007.40 | -3.8% | -45.9% | +147.7% | |
| Dec 2, 2024 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 1,091 | $11.51 | $12,557.41 | -0.3% | +32.4% | +174.2% | |
| Dec 2, 2024 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 546 | $11.51 | $6,284.46 | -0.4% | +32.4% | +174.2% | |
| Dec 2, 2024 | LQDA Liquidia Corp | Schundler Russell58 | General Counsel | Sell | 1,063 | $11.51 | $12,235.13 | -0.2% | +32.4% | +174.2% | |
| Dec 2, 2024 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 455 | $11.51 | $5,237.05 | -0.4% | +32.4% | +174.2% | |
| Dec 2, 2024 | BHC Bausch Health Companies Inc. | Carson Seana60 | EVP, General Counsel | Sell | 440 | $8.35 | $3,674.00 | -0.1% | -8.3% | -11.8% | |
| Nov 29, 2024 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 2,331 | $126.29 | $294,372.67 | -13.1% | -7.3% | +20.0% | |
| Nov 29, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 8,646 | $22.45 | $194,102.70 | -14.0% | -11.1% | +92.6% | |
| Nov 29, 2024 | CPIX Cumberland Pharmaceuticals Inc | Jones James53 | Director | Buy | 1,506 | $1.17 | $1,754.97 | +0.2% | +255.0% | +61.4% | |
| Nov 29, 2024 | CPIX Cumberland Pharmaceuticals Inc | Kazimi A J59 | Chairman And CEO | Buy | 1,506 | $1.17 | $1,754.97 | - | +255.0% | +61.4% | |
| Nov 29, 2024 | CPIX Cumberland Pharmaceuticals Inc | Young Caroline52 | Director | Buy | 647 | $1.17 | $755.45 | +0.1% | +255.0% | +61.4% | |
| Nov 29, 2024 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth54 | Director | Buy | 8,029 | $1.16 | $9,347.55 | +0.2% | +255.0% | +61.4% | |
| Nov 27, 2024 | ETST Earth Science Tech, Inc. | Saumat Giorgio R. | CEO | Buy | 104,999 | $0.15 | $15,449.87 | - | - | - | |
| Nov 27, 2024 | ALKS Alkermes Plc. | Nichols Christian Todd48 | SVP, Chief Commercial Officer | Sell | 5,208 | $29.15 | $151,813.20 | -7.9% | +19.1% | +0.9% | |
| Nov 27, 2024 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 5,000 | $0.73 | $3,649.50 | +2.5% | -19.7% | +84.1% | |
| Nov 26, 2024 | AQST Aquestive Therapeutics, Inc. | Jung Cassie | Chief Operating Officer | Sell | 44 | $4.87 | $214.06 | -100% | -39.2% | +27.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.